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Background: Treatment options for patients with advanced hepatocellular carcinoma (HCC) are often limited. In
most cases, they are not amenable to local therapies including surgery or radiofrequency ablation. The multi-kinase
inhibitor sorafenib has shown to increase overall survival in this patient group for about 3 months.
Radiation therapy is a treatment alternative, however, high local doses are required for long-term local control.
However, due to the relatively low radiation tolerance of liver normal tissue, even using stereotactic techniques,
delivery of sufficient doses for successful local tumor control has not be achieved to date.
Carbon ions offer physical and biological characteristics. Due to their inverted dose profile and the high local dose
deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. Moreover, in
comparison to photons, carbon ions offer an increased relative biological effectiveness (RBE), which can be
calculated between 2 and 3 depending on the HCC cell line as well as the endpoint analyzed.
Japanese Data on the evaluation of carbon ion radiation therapy showed promising results for patients with HCC.
Methods/Design: In the current Phase I-PROMETHEUS-01-Study, carbon ion radiotherapy will be evaluated for
patients with advanced HCC. The study will be performed as a dose-escalation study evaluating the optimal
carbon ion dose with respect to toxicity and tumor control.
Primary endpoint is toxicity, secondary endpoint is progression-free survival and response.
Discussion: The Prometheus-01 trial ist the first trial evaluating carbon ion radiotherapy delivered by intensity-
modulated rasterscanning for the treatment of HCC. Within this Phase I dose escalation study, the optimal dose of
carbon ion radiotherapy will be determined.
Trial registration: NCT 01167374
Background
Primary liver cancer is the fifth most common neoplasm
in the world, and the third most common cause of
cancer-related death; of those, hepatocellular carcinoma
(HCC) amounts to about 75-90% [1]. More than
600 000 new cases are diagnosed yearly, with and inci-
dence of 5.5 to 14.9 per 100 000 [2,3]. In some areas of
Asia, HCC is endemic, and is the most common cause
of death due to cancer [4,5]. In Europe and the USA,
HCC has shown an increase in incidence over the last
years, which is attributed to an increase in Hepatitis C-
Virus (HCV) infections [6-10]; other main risk factors
include cirrhosis, alcohol or haemochromatosis [11].
It is known, that in Europe, North America and Japan,
HCV-related HCC represents about 75% of all cases,
where as in the Asia-Pacific Region (excluding Japan)
70% of all patients with HCC are diagnosed with
chronic Hepatitis-B-Virus (HBV)-infections [12].
In Western countries, about 30-40% of all patients
with HCC are diagnosed with early stages of the disease
and potentially curative treatments such as surgical
resection, liver transplantation (TPX) or locoregional
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moembolisation can be performed, depending on liver
function and tumor burden. In well selected patient
groups, overall survival (OS) rates of 60 - 70% at 5 years
have been observed [13].
However, treatment options for patients with
advanced staged HCC are limited and this patient
group is associated with a poor prognosis [13]. In the
past, no systemic chemotherapeutic treatment regimen
has improved outcome in patients with advanced HCC
[14-16]. New substances addressing single molecular
targets, such as EGFR-inhibition with cetuximab, have
n o td e m o n s t r a t e dc o n v i n c i n gr e s u l t s[ 1 7 ] .O n l y
recently, however, the multi-kinase inhibitor sorafenib
(Nexavar
®) has been shown to be effective in patients
with HCC: In the multicenter SHARP trial (Sorafenib
Hepatocellular Carcinoma Assessment Randomized Pro-
tocol), an increase in OS in patients with advanced HCC
from a median of 7.9 months in the placebo group to
10.7 months in the sorafenib group could be demonstrated
[18]. The study included 602 patients in a double-blind
setting, and treatment with sorafenib was performed with
400 mg bid or placebo. Although OS and time to radiolo-
gical progression were increased significantly, time to
symptomatic progression (determined by the Functional
Assessment of Cancer Therapy-Hepatobiliary Syndrom
Index 8 (FHSI8) questionnaire or the occurrence of unac-
ceptable adverse events or death) was not changed. More-
over, according to the RECIST-criteria, most controlled
patients only showed stable disease in imaging, and only
2 out of 229 patients treated with sorafenib showed a par-
tial response of the HCC; no complete remissions were
observed.
Another randomized phase III trial evaluating efficacy
and safety of sorafenib in patients with advanced HCC
was performed in the Asia-Pacific region, and also
demonstrated good tolerability of sorafenib and an
increase in OS from 4.2 months to 6.5 months [19].
Again, time to symptomatic progression was unaltered
by sorafenib, and the vast majority of patients controlled
with sorafenib showed stable disease, with only 5 out of
150 partial responses and no complete remissions.
Therefore, this group of patients with advanced HCC
is still characterized by unsatisfactory outcome, and
treatment optimization is needed.
External Beam Radiotherapy has been applied for the
treatment of HCC in the past with only moderately con-
vincing clinical results. With conventional photon techni-
ques, dose tolerance of surrounding normal liver tissue
has been a major problem and has limited application of
high local doses to larger liver tumors. Radiation induced
liver disease (RILD), which is defined as a veno-occlusive
disease leading to development of ascites, icterus, increase
in liver enzymes and hepato-encephalopathy, is known to
develop with total doses of 30-35 Gy delivered to the total
liver [20]. However, more conformal radiation techniques
have been shown to be safe, however only moderately
effective, in patients with HCC, mainly due to the known
dose-response-relationship of liver tumors [20-22]. Park
et al. could show that patients treated with total doses of
>50 Gy showed significantly higher outcome and increased
rates of partial tumor responses after radiotherapy in 158
patients with HCC treated with 3D-conformal radiother-
apy with increasing doses [23]. Among other studies, this
group could show that dose was the only reproducible
prognostic factor for tumor control [23,24]. However, as
total doses are increased even using 3D-conformal photon
techniques, the rates of radiation-induced side effects
increase, and therefore application of higher and locally
effective radiation doses are limited especially in larger
tumors.
Using stereotactic photon treatments, functional nor-
mal liver tissue may be spared more effectively. In the
past, several groups have implemented extracranial
stereotactic treatment for liver tumors in single-dose or
hypofractionated settings, however, with increasing
tumor sizes which is common in HCC, dose application
is again limited [25-28].
Therefore, treatment of patients with advanced stage
HCC is often limited to systemic treatment with
sorafenib.
However, new radiation modalities such as particle
therapy offer distinct physical and biological characteris-
tics and are a promising treatment alternative for
patients with HCC.
Heavy charged particles provide the physical advan-
tage of an inverted dose profile which enables steep
dose gradients. Neighboring organs at risk and sur-
rounding normal tissue can be spared from radiation
doses. Additionally, carbon ions, as high-LET beams, are
characterized by an enhanced relative biological effec-
tiveness (RBE). For hepatocellular carcinoma cell lines,
RBE values between 2 and 3 have been reported
depending on cell line and endpoint [29,30]. In general,
high local doses are required for long-term local tumor
control in patients with HCC. The distinct physical dose
characteristics of particle therapy allow the application
of higher local doses while sparing healthy normal tis-
sue, which was a limiting factor in the application of
radiation doses for the treatments of HCC with conven-
tional radiation techniques. Results of proton radiother-
apy in patients with HCC reported from Japan are
promising, even in patients with advanced tumors
[31-37]. Carbon ions offer, additionally to the same phy-
sical benefits, an increase relative biological effective-
ness, which has been shown to be beneficial with
respect to outcome in several different tumor entities
[38]. Results from carbon ion radiotherapy for the
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high local control and response rates [38-40].
In Chiba and Tsukuba, researchers have evaluated ion
beam radiotherapy in patients with HCC showing promis-
ing results. Kawashima and colleagues treated 30 patients
with solitary HCC not amenable to surgery or local abla-
tion therapy with protons with total doses of 76 Gy E in
single fractions of 3.8 Gy E [33]. All patients had liver cir-
rhoses, which was Child A in 20 and Child B in 10
patients. No severe side effects were observed, and 2-year
actuarial local progression-free rate was 96%, with an
actuarial OS rate of 66%. Out of 30 patients, 24 developed
a complete response of the HCC. The Tsukuba group
demonstrated local control of 93% after 5 years in patients
with HCC with limited treatment options other than
radiotherapy [35]. In this study, total doses of 63-84 Gy E
proton radiotherapy were applied in a fractionated regi-
men using 13 to 27 fractions. OS rates were 62% and 33%
at 2 and 5 years. No toxicities ≥ Grade III were observed,
and treatment was well tolerated. The same group could
also demonstrate that high-dose proton radiotherapy may
be applied safely in patients with HCC associated with a
portal vein tumor thrombus, severe liver cirrhosis or even
in the aged patient population [31,34,37].
Carbon ions additionally offer a higher biological
effectiveness due to the characteristic and severe radia-
tion damages produces in target tissues. Is has been
shown that carbon ion radiotherapy leads to an
increased in local control especially in radiation resistant
tumors, such as chordomas and chondrosarcomas, ade-
noidcystic carcinomas, melanomas as well as HCC [38].
Kato an colleagues treated 24 patients with HCC with
carbon ion radiotherapy in a dose-escalation study
increasing total doses from 49.5 Gy E to 79.5 Gy E in
dose increments of 10% in a fixed 15 fraction setting
[39,40]. It could be shown that dose increase was safe
without severe treatment associated side effects, even in
the highest dose groups. The optimal dose was deter-
m i n e dt ob e7 2G yE ,w h i c hw a st h el o w e s td o s et o
show the highest local tumor control without grade III
toxicity. In this group, the overall tumor response rated
was 71%, with a complete response in 10 out of 24
patients, and a partial response on 7 out of 24 patients.
Although patient collectives in these studies on parti-
cle therapy and on the treatment of patients with sorafe-
nib are heterogeneneous, the data show that particle
therapy may be a successful treatment alternative for
patients with advanced HCC.
In the present PROMETHEUS-01 trial, carbon ion
radiotherapy will be evaluated in patients with advanced
HCC.
Since 1997, carbon ion radiation therapy is available by
the Department of Radiation Oncology, University Hospital
of Heidelberg, at the Gesellschaft für Schwerionenforschung
in Darmstadt, Germany. Clinical studies on skull base
tumors, brain tumors as well as head-and-neck-tumors
with skull base invasion treatment safety could be demon-
strated. Based on the clinical results, the Heidelberg Ion
Therapy Center (HIT) was built delivering ion beams with
equivalent technology. Worldwide, particle therapy is
available in the clinical routine in a large number of
centers.
At the University of Heidelberg, patients with HCC
are treated in the interdisciplinary setting consisting of
visceral surgery, internal medicine/gastroenterology,
radiology and radiation oncology. Therefore, patients




The trial will be performed as a single-center Phase I
Dose Finding study.
Patients fulfilling the inclusion criteria will be included
into the following Phase I dose escalation treatment
scheme shown in Table 1.
Trial Design
The study is performed as a one-armed single center
Phase I trial. The treatment schedule is shown in the
study flow chart in Figure 1.
Study objectives
The purpose of the trial is to evaluate carbon ion radio-
therapy in patients with advanced HCC. With respect to
toxicity, the optimal dose of carbon ion radiotherapy
will be determined. Therefore, the primary endpoint is
toxicity, secondary endpoints are evaluation of progres-
sion-free survival, response, and overall survival after
carbon ion radiotherapy.
Focus of the analysis is to evaluate safety and efficacy
of carbon ion radiotherapy in patients with HCC. There-
fore, the aim of the trial is to observe low rates of toxi-
city with high local doses due to effect of the altered
biology of carbon ions on HCC as well as the superior
physical characteristics.
Primary Objective
The primary objective is toxicity of carbon ion radio-
therapy and the definition of a MTD for subsequent
clinical investigation of carbon ion radiotherapy.
Table 1 Treatment scheme for dose escalation
Step 1: 4 × 10 Gy E 40 Gy E
Step 2: 4 × 11 Gy E 44 Gy E
Step 3: 4 × 12Gy E 48 Gy E
Step 4: 4 × 13 Gy E 52 Gy E
Step 5: 4 × 14 Gy E 56 Gy E
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The secondary objectives of the study are imaging
response and progression-free survival.
Patient selection: Inclusion criteria
Patients meeting all of the following criteria will be con-
sidered for admission to the trial:
- histologically confirmed HCC or diagnosis of HCC
according to AASLD-guidelines
- macroscopic tumor
- liver-confined disease without extrahepatic disease
as diagnosed by CT, MRT, ultrasound and bone scan
- minimal distance of tumor edge to the intestines of
1c m
- age ≥ 18 years of age
- Karnofsky Performance Score ≥60
- For women with childbearing potential, (and men)
adequate contraception.
- Ability of subject to understand character and indi-
vidual consequences of the clinical trial
- Written informed consent (must be available
before enrolment in the trial)
Patient selection: Exclusion criteria
Patients presenting with any of the following criteria will
not be included in the trial:
- refusal of the patients to take part in the study
- previous radiotherapy of the hepatobiliary system
- margin of < 1 cm between tumor edge and intestines
- Patients who have not yet recovered from acute
toxicities of prior therapies
- Known carcinoma < 2 years ago (excluding Carci-
noma in situ of the cervix, basal cell carcinoma,
squamous cell carcinoma of the skin) requiring
immediate treatment interfering with study therapy
Figure 1 Flow chart of the Prometheus-01 study.
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- Participation in another clinical study or observa-
tion period of competing trials, respectively
Treatment Planning
For particle therapy, patients will be immobilized using an
individually manufactured body fixation or positioning
device including abdominal pressure plates as described in
detail previously [26]. For treatment planning, contrast-
enhanced CT (3 mm slice thickness) as well as MR-
imaging will be performed for optimal target definition.
4D-CT-imaging is considered standard of care for target
definition and for position verification during the course
of radiotherapy when treating patients with moving
organs. Interstitial fiducial markers are standard of care
for treatment planning and patient positioning during
treatment and may be implanted prior to radiotherapy
within clinical routine.
Organs at risk such as the intestines, stomach, lungs,
kidney, spleen and spinal will be contoured. Dose con-
straints of normal tissue will be respected according to
Emami et al. [41].
The Gross Tumor Volume (GTV) will be defined as the
area of solid macroscopic tumor contrast enhancement
on CT and MR-imaging. The Clinical Target Volume
( C T V )w i l lb ed e f i n e da st h eG T Vp l u sam a r g i no f
5 mm. The Planning Target Volume (PTV) will include
t h eC T Vp l u sam a r g i no fa b o u t1c mt oa c c o u n tf o r
residual organ motion and setup inaccuracies.
Carbon ion RT planning is performed using the treat-
ment planning software PT-Planning (Siemens, Erlan-
gen, Germany) including biologic plan optimization.
Biologically effective dose distributions will be calculated
using the a/ß ratio for HCC as well as for the endpoint
late toxicity.
No interruptions > 4 days between during study treat-
ment are allowed.
Patient positioning directly prior to particle therapy
will be evaluated by comparison of x-rays for static
images as well as fluoroscopic imaging to determine resi-
d u a lo r g a nm o t i o ni nc o m p a r i s o nt ot h eD R R s .S e tu p
deviations > 3 mm are corrected prior to radiotherapy.
Dose Prescription Carbon Ion Radiotherapy
The intensity-controlled rasterscanning system will be
used for beam application.
Within this dose escalation study, total doses and frac-
tions will be applied according to the dosing scheme
shown in Table 1.
Treatment planning aims in the coverage of the PTV
by the 90%-isodose line.
Dose specification is based on biologic equivalent dose
because of the high relative biologic effectiveness (RBE)
of carbon ions, which differs throughout the target
volume due to its dependence on various factors. RBE
will be calculated at each voxel throughout the target
volumes and biological optimization will be performed.
Trial Duration, Schedule and Follow-up
The primary endpoint is acute toxicity of carbon ion
radiotherapy observed within 30 days of study
treatment.
Patients are scheduled for follow-up visits every
4 weeks after completion of carbon ion radiotherapy for
the first 3 months, thereafter in 2-months intervals or as
needed clinically including contrast-enhanced MRI as
well as thorough clinical-neurological and haematologi-
cal assessment. These follow-up visits are in line with
standard care outside of clinical trials.
The last patient included into the study will be fol-
lowed for at least 3 months after study treatment. This
is considered the final study visit. All other patients will
be followed regularly as described in detail until death
or until 3 months after LPI.
The overall duration of the trial is expected to be
approximately 24 months.
Assessment of Efficacy Parameters
- Progression-free Survival and Treatment Response -
Efficacy of the treatment will be recorded according to
the RECIST-Criteria (Revised Guidelines, Version 1.1,
2009 [42]):
Complete Response (CR) Disappearance of all target
lesions.
Partial Response (PR) at least 30% decrease in the sum
of diameters of target lesions, taking a reference the
baseline sum diameters.
Progressive Disease (PD) At least a 20% increase in the
sum of diameters of target lesions, taking as reference
the smallest sum on study (this includes the baseline
sum if that is the smallest on study). In addition to the
relative increase of 20%, the sum must also demonstrate
an absolute increase of a t least 5 mm (Note: The
appearance of one or more new lesions is also consid-
ered progression).
Stable Disease (SD) Neither sufficient shrinkage to qua-
lify for PR nor sufficient increase to qualify for PD, tak-
ing as reference the smallest sum diameters while on
study.
The principal investigator or study co-ordinator may
be contacted for further discussion on a case by case
basis.
Assessment of Safety Parameters
This study will use the International Common Termi-
nology Criteria for Adverse Events (CTCAE) version 4.0
for toxicity and adverse event reporting. A copy or the
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http://ctep.cancer.gov/protocolDevelopment/electroni-
c_applications/ctc.htm
Safety and toxicity of the study treatment will be eval-
uated by clinical examination, haematological evaluation
as well as imaging studies (MRI or CT).
Statistical calculations for trial sample size
Study hypothesis
The study is designed to demonstrate that carbon ion
radiotherapy is safe for the treatment of HCC. The aim
of the study is to evaluate the optimal dose tolerated
with respect to toxicity.
Unacceptable toxicity (DLT) is defined as any irrever-
sible grade 4 toxicity during a time frame of 30 days as
classified by CTCAE version 4.0.
Statistical Methods
Sample Size Calculation
The calculation of sample size for the PROMETHEUS-
01 trial is based on the traditional dose escalation
scheme. DLT are considered any irreversible Grade 4
toxicity classified by CTCAE version 4.0 after study
treatment.
Patients are treated in cohorts of three each receiving
the same dose.
For observation of DLT, patients are observed for
30 days after study treatment. If the last patient of the
cohort is observed 30 days after study treatment,
patients of the next cohort may be recruited.
If none of the three patients shows a DLT, the next
cohort of three patients receives the next higher dose as
described above.
Otherwise, if at least one patient of the cohort devel-
ops a DLT (1/3), a second cohort of three patients is
treated at the same dose level without escalating the
dose.
If exactly one out of the six patients (1/6) treated
exhibits DLT, the trial continues as planned at the next
higher dose level.
If two or more patients out of the six exhibit a DLT,
the dose escalation stops at that level and the next
lower level is considered as the MTD. When the escala-
tion has stopped, additional patients will be treated at
the MTD to a total of nine patients.
This trial is conducted to choose the MTD of carbon
ion radiotherapy between five dose levels. Therefore the
sample size at maximum is 33 patients (4 dose levels
with at maximum 6 patients and 9 patients at the MTD).
Analysis Variables
Primary endpoint is the MTD chosen between the five
dose limits based on the traditional dose escalation
scheme. Any unpredictable of irreversible grade 4 toxi-
city possibly, probably or definitely related the study
treatment occurring 30 days after completion of study
treatment is considered as dose limiting toxicity.
Secondary endpoints are the collection of safety data
on the dose levels used in this trial as well as response,
progression-free survival, and overall survival.
Analysis Populations
The Analysis set for primary endpoint consists of all
patients treated at least once with the study treatment.
A total of five analysis sets (one per dose level) will be
considered.
Analysis set for secondary endpoints: All patients will
be included for analysis for secondary endpoints treated
at least one with the study treatment. Additionally, a
total of five analysis sets (one per dose level) will be
considered to determine any differences in secondary
endpoints between the 5 dose levels.
Statistical Methods
Confirmatory Analysis
No confirmatory statistical analysis will be performed.
The MTD is determined according to the traditional
dose-escalation scheme for Phase I trials in oncology.
Descriptive Analysis
Descriptive summary tables will be presented on base-
line patient characteristics as well as for all safety para-
meters by dose level. Absolute and relative frequencies
are reported for all toxicities of the CTC list (NCI CTC-
AE Version 4.0) by distinguishing the grading and the
assessment of the relation to treatment. Within this
study, dose limiting toxicities (DLTs) are defined as any
grade IV toxicity according to CTCAE Version 4.0 pos-
sibly, probably or definitely associated to study treat-
ment during 30 days after completion of therapy.
A description of the individual load of toxicity of each
patient will be made separately using individual descrip-
tions eventually supported by graphical methods.
Interim Analyses
Besides the planned analysis during the dose escalation,
no further interim analyses are planned.
Data Handling, Storage and Archiving of Date
According to the §13 of the German GCP-Regulation all
important trial documents (e.g. CRF) will be archived
for at least 10 years after the trial termination.
According to the §28c of the German X-Ray Regula-
tion (RöV) and the §87 of the German Radiation Protec-
tion Regulation (StrlSchV) the informed consent forms
including patients’ consent for trial participation, appli-
cation of irradiation and data transmission to the com-
petent authority will be archived for at least 30 years
after the trial termination.
The Study Center at the Department of Radiation
Oncology Define will be responsible for archiving all
relevant data.
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The procedures set out in this trial protocol, pertaining
to the conduct, evaluation, and documentation of this
trial, are designed to ensure that all persons involved in
the trial by Good Clinical Practice (GCP) and the ethical
principles described in the applicable version of the
Declaration of Helsinki (2008 Version of the Declaration
of Helsinki, adopted at the 59th WMA General Assem-
bly, Seoul, October 2008).
The trial will be carried out in keeping with local legal
and regulatory requirements.
Ethics, informed consent and safety
A positive Ethics Vote was obtained by the Local Ethics
Committee of the medical Faculty at the University of
Heidelberg, Germany.
B e f o r es t u d yr e c r u i t m e n t ,ap o s i t i v ev o t eo ft h eB u n -
desamt für Strahlenschutz (BfS) has been obtained.
Before being admitted to the clinical trial, the subject
must consent to participate after the nature, scope, and
possible consequences of the clinical trial have been
explained in a form understandable to him or her. The
subject must give consent in writing.
Treatment at tumor progression
For tumor progression, treatment alternatives will be evalu-
ated and discussed interdisciplinary considering options of
surgical resection, systemic treatment such as chemotherapy,
a second course of radiation therapy, or other.
Discussion
Carbon ion radiotherapy offers distinc physical as well
as biological benefits and has shown to be a promising
treatment alternative for patients with HCC. Previous
studies published by Japanese particle therapy centers
have shown excellent results with respect to local con-
trol as well as overall survival in patients with HCC
treated with carbon ion radiotherapy. In the present
trial, the Phase I dose escalation concept will evaluated
th optimal dose of carbonion radiotherapy for the treat-
ment of HCC when delivered by intensity-controlled
rasterscanning.
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